In addition, our data have strong clinical implication since current therapies designed to target the induced HIF2α/VEGF signals due to mutant or suppressed VHL (via promoter hyper-methylation) only yield limited efficacy in select RCC patients [6]. The gene discussed is EPAS1; the disease is renal cell carcinoma.